Hereditary Non-polyposis Colorectal Cancer: Prevention and Therapeutic Options
- 135 Downloads
Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer (HNPCC), is the most common hereditary colorectal cancer (CRC) syndrome. The first and foremost preventive measure is to identify patients with LS among CRC patients. This requires the screening of colorectal cancer through polymerase chain reaction-based microsatellite instability (MSI) testing or immunohistochemistry to look for a loss of expression of one of the mismatch repair (MMR) proteins and the referral of selected patients to genetic counseling. In LS patients, annual or biannual complete colonoscopy with chromoendoscopy is the only validated way to significantly reduce mortality related to CRC with the greatest quality-adjusted life expectancy benefit compared with prophylactic surgery. In the case of diagnosis of colonic cancer, a subtotal colectomy with an ileo-rectal anastomosis is recommended, in order to decrease the risk of metachronous CRC. However, segmental surgery can be discussed on an individual basis. Chemoprevention with aspirin seems to be efficient in decreasing colorectal cancer risk in LS, but the minimum effective dose and potential adverse events associated with long-term use are not yet known. The option of taking low-dose aspirin might be discussed with mutated gene carriers regarding the benefit and risks of the treatment.
KeywordsLynch syndrome HNPCC MMR genes Molecular screening Colorectal cancer Guidelines Endoscopic screening Chromoendoscopy Subtotal colectomy Aspirin Chemoprevention
Compliance with Ethics Guidelines
Conflict of Interest
Marion Dhooge, Romain Coriat, Sophie Grandjouan, Catherine Brezault, Johann Dreanic, and Stanislas Chaussade declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.•Vasen HFA, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62(6):812–23. European recommendations for clinical management of Lynch syndrome.CrossRefPubMedCentralPubMedGoogle Scholar
- 12.••Pérez-Carbonell L, Ruiz-Ponte C, Guarinos C, Alenda C, Payá A, Brea A, et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut. 2012;61(6):865–72. The authors show that routine molecular screening has better sensitivity for detecting mutation carriers than the Bethesda guidelines.CrossRefPubMedGoogle Scholar
- 13.Tranø G, Sjursen W, Wasmuth HH, Hofsli E, Vatten LJ. Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based study. Br J Cancer. 2010;102(3):482–8.CrossRefPubMedCentralPubMedGoogle Scholar
- 17.Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11(1):35–41.Google Scholar
- 18.Mange S, Bellcross C, Cragun D, Duquette D, Gorman L, Hampel H, et al. Creation of a network to promote universal screening for Lynch syndrome: the Lynch Syndrome Screening Network. J Genet Couns. 2014.Google Scholar
- 26.Hurlstone DP, Karajeh M, Cross SS, McAlindon ME, Brown S, Hunter MD, et al. The role of high-magnification-chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: a prospective « back-to-back » endoscopic study. Am J Gastroenterol. 2005;100(10):2167–73.CrossRefPubMedGoogle Scholar
- 32.•Provenzale D, Jasperson K. NCCN clinical practice guidelines in oncology for genetic/familial high-risk assessment: colorectal cancer. National Comprehensive Cancer Network; 2014. US recommendations for clinical management of familial high risk of Colorectal Cancer including Lynch Syndrome.Google Scholar
- 33.••Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304–10. The authors show that MSH6 mutations are associated with markedly lower cancer risks than MLH1 or MSH2 mutations.CrossRefPubMedGoogle Scholar
- 34.••Ten Broeke SW, Brohet RM, Tops CM, Van der Klift HM, Velthuizen ME, Bernstein I, et al. Lynch syndrome caused by Germline PMS2 mutations: delineating the cancer risk. J Clin Oncol. 2014. The authors reported markedly lower risks of colorectal cancer and endometrial cancer in PMS2 mutations carriers than those previously reported for the other MMR mutations.Google Scholar
- 36.Buecher B, Kirzin S, Karoui M, Ansquer Y, Parc Y. Chirurgie prophylactique des cancers avec prédisposition génétique. Syndrome HNPCC/Lynch. Institut National du Cancer; 2009 p. 47.Google Scholar
- 42.Single-stage treatment for malignant left-sided colonic obstruction: a prospective randomized clinical trial comparing subtotal colectomy with segmental resection following intraoperative irrigation. The SCOTIA Study Group. Subtotal colectomy versus on-table irrigation and anastomosis. Br J Surg. 1995;82(12):1622–1627.Google Scholar
- 45.•Burn J, Gerdes A-M, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081–7. The authors show a decrease in colorectal cancer risk by using aspirin in HNPCC patients.CrossRefPubMedCentralPubMedGoogle Scholar